Related Experiment Videos
A dimeric bispecific miniantibody combines two specificities with avidity
K M Müller1, K M Arndt, A Plückthun
1Biochemisches Institut, Universität Zürich, Switzerland.
FEBS Letters
|August 26, 1998
Summary
Researchers engineered a novel dimeric bispecific (DiBi) miniantibody, a small protein with dual specificity for immunotherapy and biotechnology applications. This bispecific antibody technology offers enhanced avidity in a compact format.
Area of Science:
- Biotechnology
- Immunotherapy
- Protein Engineering
Background:
- Bispecific antibodies offer versatile applications in immunotherapy and biotechnology.
- Engineering novel antibody formats can enhance therapeutic capabilities.
Purpose of the Study:
- To develop a novel bispecific miniantibody format (DiBi) with dual specificity.
- To demonstrate the functional expression and binding capabilities of the DiBi miniantibody.
Main Methods:
- Gene fusion of single-chain variable fragments (scFv) with a helical dimerization domain.
- Expression of the bispecific protein in E. coli.
- Binding analysis using sandwich surface plasmon resonance (SPR) biosensor (BIAcore) measurements.
Main Results:
- Successfully expressed a functional bispecific dimeric miniantibody (DiBi) in E. coli.
- The DiBi miniantibody exhibits dual specificity and preserved natural avidity.
- Demonstrated generality with scFv 425 (anti-EGF-receptor) in combination with anti-CD2, anti-phosphorylcholine, and anti-fluorescein scFvs.
Conclusions:
- The DiBi miniantibody is a novel, small-sized (120 kDa) bispecific protein format.
- This technology enables the creation of bispecific antibodies with preserved avidity for diverse applications.